$GLENMARK Glenmark Pharmaceuticals reported a strong Q4 FY26

Glenmark Pharmaceuticals reported a strong Q4 FY26 performance with net profit doubling year‑on‑year, driven by robust domestic sales and cost efficiency. The market responded positively, with the stock gaining over 3%. 💊 Glenmark Pharma Q4 FY26 Highlights Metric Q4 FY26 Q4 FY25 Change Revenue from Operations ₹2,950 crore ₹2,750 crore +7.3% YoY Net Profit ₹761 crore ₹380 crore +100% YoY EBITDA Margin 22.5% 18.2% Improved by 430 bps EPS ₹27.8 ₹13.9 +100% YoY 🧪 Segment Performance India Business: ₹1,050 crore (+9% YoY) — strong dermatology and respiratory portfolio. US Business: ₹1,120 crore (+5% YoY) — steady growth in generics and specialty products. API Segment: ₹420 crore (+11% YoY) — higher export demand. Glenmark Life Sciences (subsidiary): ₹580 crore revenue (+8% YoY). ⚠️ Key Takeaways Strong domestic and API growth offset global pricing pressure. Cost optimization and lower R&D spend boosted margins. Management guided for 10–12% revenue growth in FY27.